103 related articles for article (PubMed ID: 15906186)
1. American association for cancer research--96th annual meeting. Kinases.
Phillips T; Collins T; Davies J
IDrugs; 2005 Jun; 8(6):458-60. PubMed ID: 15906186
[No Abstract] [Full Text] [Related]
2. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Moasser MM; Srethapakdi M; Sachar KS; Kraker AJ; Rosen N
Cancer Res; 1999 Dec; 59(24):6145-52. PubMed ID: 10626805
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of serine/threonine kinases.
Lee JC; Adams JL
Curr Opin Biotechnol; 1995 Dec; 6(6):657-61. PubMed ID: 8527836
[TBL] [Abstract][Full Text] [Related]
4. In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives.
Rossignol E; Debiton E; Fabbro D; Moreau P; Prudhomme M; Anizon F
Anticancer Drugs; 2008 Sep; 19(8):789-92. PubMed ID: 18690090
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of Src inhibition on medullary thyroid cancer.
Liu Z; Falola J; Zhu X; Gu Y; Kim LT; Sarosi GA; Anthony T; Nwariaku FE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3503-9. PubMed ID: 15240638
[TBL] [Abstract][Full Text] [Related]
6. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
7. American Association of Cancer Research--95th annual meeting. Kinases. 27-31 March, 2004, Orlando, FL, USA.
Kibble A; Davies J
IDrugs; 2004 May; 7(5):411-3. PubMed ID: 15154094
[No Abstract] [Full Text] [Related]
8. American Association for Cancer Research--99th Annual Meeting. Clinical and preclinical data on promising therapeutics.
Karger GA; Lee W
IDrugs; 2008 Jun; 11(6):415-7. PubMed ID: 18509781
[No Abstract] [Full Text] [Related]
9. American Association for Cancer Research--94th Annual Meeting. New compounds. 11-14 July 2003, Washington, DC, USA.
Mackay J; Williams L
IDrugs; 2003 Aug; 6(8):733-5. PubMed ID: 12971387
[No Abstract] [Full Text] [Related]
10. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
11. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways.
Kamiguti AS; Harris RJ; Slupsky JR; Baker PK; Cawley JC; Zuzel M
Oncogene; 2003 Apr; 22(15):2272-84. PubMed ID: 12700663
[TBL] [Abstract][Full Text] [Related]
12. Pentosan polysulfate, a potent anti HIV and anti tumor agent, inhibits protein serine/threonine and tyrosine kinases.
Srivastava AK; Sékaly RP; Chiasson JL
Mol Cell Biochem; 1993 Mar; 120(2):127-33. PubMed ID: 7683745
[TBL] [Abstract][Full Text] [Related]
13. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitors in cancer therapy: a look ahead.
Sedlacek HH
Drugs; 2000 Mar; 59(3):435-76. PubMed ID: 10776829
[TBL] [Abstract][Full Text] [Related]
15. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
16. PTHrP stimulated by the calcium-sensing receptor requires MAP kinase activation.
MacLeod RJ; Chattopadhyay N; Brown EM
Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E435-42. PubMed ID: 12388158
[TBL] [Abstract][Full Text] [Related]
17. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
18. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
[TBL] [Abstract][Full Text] [Related]
19. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
20. MEK wars, a new front in the battle against cancer.
Duesbery NS; Webb CP; Vande Woude GF
Nat Med; 1999 Jul; 5(7):736-7. PubMed ID: 10395314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
